HanAll's Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China
HanAll Biopharma (KRX: 009420.KS) announced that its partner Harbour BioMed had completed the first dosing of the first patient in Phase 2 of batoclimab in thyroid eye disease (TED) in China.
For more information, please refer to the link below.
- HBM's press release link: https://www.harbourbiomed.com/news/168.html
NextHanAll Biopharma Reports Third Quarter 2021 Results
PrevHanAll's Partner HBM Initiates Phase 3 of Batoclimab in gMG in China